Paper Details

  1. Home
  2. Paper Details

Randomised controlled trial of lymphoblastoid interferon for chronic active hepatitis B.

Author: AlexanderG J, AndersonM G, HarrisonT J, Murray-LyonI M, ZuckermanA J

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This study investigated the effectiveness of interferon treatment for 30 men with chronic hepatitis B. Patients were randomly assigned to receive either interferon or no treatment. Interferon was given daily for 28 days. While all patients experienced temporary side effects like fatigue and flu-like symptoms, interferon successfully suppressed the hepatitis B virus during treatment. However, this effect was only temporary, and after one year, there was no significant difference in viral markers between the treated and untreated groups. The study concludes that this daily interferon regimen was less effective than other treatments using interferon three times a week for three months.
Paper Details　
Original Abstract of the Article :
Thirty male patients (28 homosexual or bisexual) with biopsy proven chronic active hepatitis B were randomised to receive lymphoblastoid interferon (Wellferon) or no treatment. All patients were HBeAg-positive and had continuing viral replication. Interferon was given as a single daily i.m. injectio...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/s0168-8278(86)80124-6

データ提供：米国国立医学図書館（NLM）

Lymphoblastoid Interferon for Chronic Active Hepatitis B: A Randomized Trial

The realm of viral hepatitis, particularly chronic active hepatitis B, presents a formidable challenge to medical professionals. This randomized controlled trial delves into the efficacy of lymphoblastoid interferon (Wellferon) as a treatment for this persistent infection. The study involved 30 male patients, predominantly with a history of homosexual or bisexual activity, all of whom exhibited chronic active hepatitis B confirmed by biopsy and ongoing viral replication. The researchers sought to unravel the effectiveness of Wellferon in suppressing viral replication and improving liver function.

Limited Success: Transient Effects and No Long-Term Improvement

The study revealed that while Wellferon effectively suppressed hepatitis B viral replication during the treatment period, this effect was transient and did not persist beyond the 28-day treatment duration. Despite the initial suppression, after a year of follow-up, no significant differences were observed between the treatment and control groups, suggesting a lack of long-term benefit. The researchers also noted that the treatment regimen employed in this study appeared less effective compared to other regimens reported by other centers. This finding underscores the importance of considering different treatment approaches and optimizing regimens to maximize clinical benefits.

Navigating the Desert of Hepatitis B Treatment: A Need for Continued Exploration

The study's results underscore the need for continued research and development of effective therapies for chronic active hepatitis B. While Wellferon showed transient benefits, the lack of lasting improvement highlights the complexity of managing this viral infection. The researchers' careful evaluation of treatment duration and regimen effectiveness provides valuable insights for future research endeavors, paving the way for more effective and sustainable treatment options for those affected by chronic active hepatitis B.

Dr.Camel's Conclusion

Lymphoblastoid interferon (Wellferon) showed a temporary effect on hepatitis B viral replication but failed to provide long-term improvement. This study underscores the need for continued research and development of effective and sustainable therapies for chronic active hepatitis B.

Date :
  1. Date Completed 1987-08-05
  2. Date Revised 2019-08-17
Further Info :

Pubmed ID

3298409

DOI: Digital Object Identifier

10.1016/s0168-8278(86)80124-6

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.